HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.

AuthorsC M Zwaan, D Reinhardt, H Jürgens, D R Huismans, K Hählen, O P Smith, A Biondi, E R van Wering, J Feingold, G J L Kaspers
JournalLeukemia (Leukemia) Vol. 17 Issue 2 Pg. 468-70 (Feb 2003) ISSN: 0887-6924 [Print] England
PMID12592351 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD33 protein, human
  • Immunotoxins
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab
Topics
  • Aminoglycosides
  • Anti-Bacterial Agents (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD (blood)
  • Antigens, Differentiation, Myelomonocytic (blood)
  • Child
  • Child, Preschool
  • Chromosome Deletion
  • Female
  • Gemtuzumab
  • Humans
  • Immunotoxins (therapeutic use)
  • Infant
  • Karyotyping
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, genetics)
  • Sialic Acid Binding Ig-like Lectin 3

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: